Managing dopamine agonist withdrawal syndrome in Parkinson's disease

Progress in Neurology and Psychiatry

Volumn 15, Issue 4, 2011, Pages 4-

  Lindahl, Andrea J ^a   Macmahon, Douglas G ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; CARBAMAZEPINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ZONISAMIDE;

CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; GENETIC PREDISPOSITION; HELP SEEKING BEHAVIOR; HUMAN; IMPULSE CONTROL DISORDER; NOTE; PARKINSON DISEASE; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; WITHDRAWAL SYNDROME;

EID: 79961232024     PISSN: 13677543     EISSN: 1931227X     Source Type: Journal    
DOI: 10.1002/pnp.203     Document Type: Note

References (19)

1. Driver-Dunkley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61:422-3.
2. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson's disease. Arch Neurol 2010;67(5):589-95.
3. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson's disease. Arch Neurol 2010;67(1):58-63.
4. http://forum.parkinson.org/index.php?/topic/10922-going-through-daws-when-getting-off-mirapex-due-to-icd/ accessed 23.5.11.
5. Isaias IU, Siri C, Cilia R, et al. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Movement Disord 2008;23(3):411-5.
6. Antonini A, Siri C, Santangelo G, et al. Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. Movement Disord 2011;26(3):464-8. doi: 10.1002/mds.23501. Epub Feb 10, 2011.
7. Cilia R, van Eimeren T. Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. Brain Struct Funct 2011; May 4. [Epub ahead of print]
8. Schlesinger I, Erikh I, Zaaroor M. Dopamine agonist withdrawal syndrome: the apomorphine solution. Arch Neurol 2010; 67(9):1155, author reply 1156.
9. Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord 2007;13:369-71.
10. Halbig TD, Tse W, Frisina PG, et al. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol 2009;16:493-7.
11. Demetriades P, Rickards H, Cavanna AE. Impulse control disorders following deep brain stimulation of the subthalamic nucleus in Parkinson's disease: clinical aspects. Parkinsons Dis 2011;2011:658415.
12. Nirenberg MJ. Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery. Brain 2010;133(11): e155, author reply 156. Epub 2010, Jul 21.
13. Gerschlager W, Bloem BR. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions. Movement Disord 2009;24:1858-60.
14. Bach JP, Oertel WH, Dodel R, Jessen F. Treatment of hypersexuality in Parkinson's disease with carbamazepine - a case report. Movement Disord 2009;24:1241-42.
15. Thomas A, Bonanni L, Gambi F, et al. Patho -logical gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010;68:400-4.
16. Bermejo PE, Ruiz-Huete C, Anciones B. Zonis -amide in managing impulse control disorders in Parkinson's disease. J Neurol 2010;257:1682-5.
17. Rotondo A, Bosco D, Plastino M, et al. Clozapine for medication-related pathological gambling in Parkinson disease. Movement Disord 2010;25:1994-5.
18. Wingo TS, Evatt M, Scott B, et al. Impulse control disorders arising in 3 patients treated with rotigotine. Clin Neuropharmacol 2009; 32(2):59-62.
19. Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsivecompulsive disorders in Parkinson's disease. Movement Disord 2009;24(10):1461-7. [QUIP questionnaire]